Sugi Predict

Sugi Predict / Targets / APBA1

APBA1

Amyloid-beta A4 precursor protein-binding fam · Q02410 · APBA1 on Sugi Atlas →

41,724 patent compounds predicted against APBA1, 29,665 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL116036 SCHEMBL116036 0.62 3/20
SCHEMBL106017 SCHEMBL106017 0.53 3/20
SCHEMBL152799 SCHEMBL152799 0.53 3/20
SCHEMBL363703 SCHEMBL363703 0.96 2/20
SCHEMBL159873 SCHEMBL159873 0.71 2/20
SCHEMBL62930 SCHEMBL62930 0.69 2/20
SCHEMBL95883 SCHEMBL95883 0.68 2/20
SCHEMBL64694 SCHEMBL64694 0.63 2/20
SCHEMBL252991 SCHEMBL252991 0.60 2/20
SCHEMBL331470 SCHEMBL331470 0.58 2/20
SCHEMBL109267 SCHEMBL109267 0.55 2/20
SCHEMBL152254 SCHEMBL152254 0.55 2/20
SCHEMBL87617 SCHEMBL87617 0.53 2/20
SCHEMBL149927 SCHEMBL149927 0.53 2/20
SCHEMBL152219 SCHEMBL152219 0.53 2/20
SCHEMBL27740 SCHEMBL27740 0.52 2/20
Acenaphthoquinone Acenaphthoquinone (SCHEMBL141538) 0.52 2/20
SCHEMBL303331 SCHEMBL303331 0.51 2/20
SCHEMBL151352 SCHEMBL151352 0.50 2/20
SCHEMBL266792 SCHEMBL266792 0.48 2/20

Clinical trials — most relevant to APBA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation PHASE2/PHASE3RECRUITING
Longitudinal Study of Brain Amyloid imaGing in MEMENTO PHASE3COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. PHASE2/PHASE3COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 PHASE2/PHASE3ACTIVE_NOT_RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation PHASE2/PHASE3RECRUITING
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET) PHASE2COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis PHASE1/PHASE2COMPLETED
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY PHASE1COMPLETED
Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics PHASE1RECRUITING
Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD PHASE1COMPLETED
Exploratory and Safety Study of [F-18]W372 EARLY_PHASE1COMPLETED
Clearance Mechanisms in Atypical Neurodegenerative Diseases nanUNKNOWN
Late Onset Alzheimer's Disease nanRECRUITING
Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy nanUNKNOWN
Dominantly Inherited Alzheimer Network (DIAN) nanRECRUITING
Effects of an 8 Component Botanical Supplement on Mild and Moderate Alzheimer's Patients nanCOMPLETED
An Evaluation of Low Level Laser Light Therapy on Improving the Symptoms of Alzheimer's Disease nanCOMPLETED
Alzheimer's Disease Genetics Study nanRECRUITING
The Genetic Characterization of Dementia nanCOMPLETED
Identification of New FTLD Genes nanUNKNOWN
Is Tau Protein Linked to Mobility Function? nanCOMPLETED
The Evaluation and Follow-up of Individuals With Memory Disorder nanCOMPLETED
Apolipoprotein E Gene and Functional MRI nanCOMPLETED
Disclosing Dementia Risk Based on Plasma Phosphorylated Tau nanCOMPLETED
Biomarker Study for Alzheimer's Disease nanCOMPLETED
Phenotypic and Molecular Characterisation of Cerebral Amyloid Angiopathy nanRECRUITING
The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease nanRECRUITING
PET Measures of CSF Clearance in Preclinical Alzheimer's Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a APBA1 binder may also engage these)

ProteinNameSimilarity
B2RUJ5 — 1.000 B2RUJ5 →
O35430 — 1.000 O35430 →
Q99767 — 0.986 Q99767 →
P98084 — 0.985 P98084 →
Q5RD33 — 0.985 Q5RD33 →
O35431 — 0.983 O35431 →
Q8BIE6 — 0.959 Q8BIE6 →
A1YFY6 — 0.958 A1YFY6 →
Q8N108 — 0.958 Q8N108 →
Q6ZMZ0 — 0.958 Q6ZMZ0 →
Q9P2Q2 — 0.957 Q9P2Q2 →
Q5REE1 — 0.957 Q5REE1 →
Q9Z1T4 — 0.957 Q9Z1T4 →
Q9UPW8 — 0.957 Q9UPW8 →
P81133 — 0.957 P81133 →
Q8WXI2 — 0.956 Q8WXI2 →
A2T6X9 — 0.956 A2T6X9 →
Q96SB3 — 0.955 Q96SB3 →
A2A7Q9 — 0.955 A2A7Q9 →
TLK2 Serine/threonine-protein kinase tousled-like 2 0.955 landscape →
Q4KUS2 — 0.955 Q4KUS2 →
P49418 — 0.954 P49418 →
O55047 — 0.953 O55047 →
Q80YA9 — 0.953 Q80YA9 →
O75446 — 0.953 O75446 →
CBL E3 ubiquitin-protein ligase CBL 0.953 landscape →
Q56A18 — 0.952 Q56A18 →
Q6R891 — 0.952 Q6R891 →
BCR Breakpoint cluster region protein 0.952 landscape →
O35274 — 0.952 O35274 →